Last week, the Food and Drug Administration declared an end to the shortage of Eli Lilly’s tirzepatide, sold under the brand name Mounjaro for diabetes and Zepbound for obesity. The move was a ...

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...

Ozempic, Wegovy or Mounjaro: the battle of the weight-loss injections - As weight-loss injections emerge as key players in ...

The Food and Drug Administration on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, from its shortage list ...

Eli Lilly has suffered a major setback after the US regulator rejected its rheumatoid arthritis pill, baricitinib, sending the company’s share price plummeting. Lilly received a letter from the ...

With the most potent weight-loss shot and a pipeline of 11 experimental treatments, including what is widely expected to be the first approved small molecule GLP-1 pill, Eli Lilly stands to be the ...

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

Surging demand for weight loss drugs Wegovy and Zepbound from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) has fueled concerns over a significant risk linked to the popular drug class: loss of ...

In July Mr Major held 2.2pc of his fund in Structure Therapeutics, a San Francisco-based company trialling a weight-loss pill that may be easier for patients to take than Novo and Lilly’s ...